OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
LAB282 is an exciting £13m public private partnership between the University, Oxford Sciences Innovation, and the international drug discovery company Evotec AG, to accelerate drug discovery in Oxford. There is currently a lack of funding to help translate basic research in disease-related biological pathways into focused drug discovery programmes. LAB282 seeks to address this unmet need, to stimulate the formation of new projects and companies to develop ground-breaking therapies, and ultimately to generate patient benefit. LAB282 projects will be sourced from across the research activities in the University of Oxford, from any disease area and will include all therapeutic modalities. Successful applicants will partner with Evotec to gain access to their industry leading drug discovery services through an award based scheme. This talk will detail the LAB282 initiative and how to apply.
